NDC product
Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride
NDC 58602-703 · Aurohealth LLC
Key facts
| Product NDC | 58602-703 |
|---|---|
| Proprietary name | Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride |
| Nonproprietary name | Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride |
| Substances | CETIRIZINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE |
| Dosage form | TABLET, FILM COATED, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | Aurohealth LLC |
| Product type | HUMAN OTC DRUG |
| Marketing category | ANDA |
| Application number | ANDA212409 |
| Pharmacologic classes | Adrenergic alpha-Agonists [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], alpha-Adrenergic Agonist [EPC] |
| Marketing start | Mar 8, 2023 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: